Company Filing History:
Years Active: 2012-2015
Title: Eva Maria Dahlén: Innovator in Biopharmaceuticals
Introduction
Eva Maria Dahlén is a prominent inventor based in Arlöv, Sweden. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of interleukin-1 receptor antagonists. With a total of 2 patents, her work is pivotal in advancing therapeutic options for various diseases.
Latest Patents
Dahlén's latest patents focus on mutants of interleukin-1 receptor antagonists. The inventions provide isolated polypeptides that comprise variant amino acid sequences, which retain the biological activity of the wild type IL-IRa. These polypeptides are designed to include specific amino acid substitutions, enhancing their therapeutic potential. Additionally, the patents detail pharmaceutical compositions that utilize these polypeptides for treating conditions that can be addressed by inhibiting IL-1 receptor functions.
Career Highlights
Eva Maria Dahlén is associated with Alligator Bioscience AB, a company known for its innovative approaches in the biopharmaceutical sector. Her work at the company has been instrumental in developing new treatments that leverage her patented inventions.
Collaborations
Dahlén collaborates with notable colleagues, including Patrick Thomas Höjman and Marie Asa Ingegerd Karlsson. These partnerships enhance the research and development efforts within her field.
Conclusion
Eva Maria Dahlén's contributions to biopharmaceuticals through her patents and collaborations underscore her role as a leading inventor in the industry. Her work continues to pave the way for innovative treatments that address critical health challenges.